ID

24772

Descripción

Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00569114

Link

https://clinicaltrials.gov/show/NCT00569114

Palabras clave

Versiones (1)
  1. 16/8/17 16/8/17 -
Subido en

16 de agosto de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Non-small Cell Lung Cancer NCT00569114

Inglés

Eligibility Non-small Cell Lung Cancer NCT00569114

1 formularios  
Criteria
Descripción

Criteria

histogically or pathologically determined relapsed/recurrent stage iiib (plueral effusion) or iv nsclc.
Descripción

Non-small cell lung cancer recurrent TNM clinical staging | Pleural effusion

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0278517
UMLS CUI [1,2]
C3258246
UMLS CUI [2]
C0032227
measurable or evaluable disease as defined by recist
Descripción

Measurable Disease | Evaluable Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1516986
must have failed at least one prior chemotherapy regimen or have refused chemotherapy.
Descripción

Chemotherapy Regimen Quantity failed | Chemotherapy Refused

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0231175
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C1705116
ecog perfromance status of 0,1, or 2.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
exclusion criteria (include but are not limited to):
Descripción

Exclusion Criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
radiation therapy (excluding cns therapy) < 2 weeks, chemotherapy, non-cytotoxic investigational agents or high dose corticosteroids within 3 weeks of intitating therpy or patients who have not recovered from adverse effects due to agents administered more than 3 weeks earlier.
Descripción

Therapeutic radiology procedure | Exception Therapeutic procedure Central Nervous System | Chemotherapy | Investigational New Drugs Non-Cytotoxic | Adrenal Cortex Hormones High dose | Adverse effects of medical drugs Recovery Lacking

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0087111
UMLS CUI [2,3]
C3714787
UMLS CUI [3]
C0392920
UMLS CUI [4,1]
C0013230
UMLS CUI [4,2]
C2827065
UMLS CUI [5,1]
C0001617
UMLS CUI [5,2]
C0444956
UMLS CUI [6,1]
C0810090
UMLS CUI [6,2]
C2004454
UMLS CUI [6,3]
C0332268
evidence of new york heart associatation class iii or greater cardiac disease.
Descripción

Heart Disease New York Heart Association Classification

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0018799
UMLS CUI [1,2]
C1275491
history of myocardial infarction, stroke, or cardiovascular intervention within the last 12 months.
Descripción

Myocardial Infarction | Cerebrovascular accident | Intervention Cardiovascular

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0038454
UMLS CUI [3,1]
C0184661
UMLS CUI [3,2]
C3887460
patients on anti-platlet drugs or anticoagulants such as placix and coumadin.
Descripción

Antiplatelet Agents | Anticoagulants | Plavix | Coumadin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0085826
UMLS CUI [2]
C0003280
UMLS CUI [3]
C0633084
UMLS CUI [4]
C0699129
systemic central nervous system metastases. the patient must be stable after radiotherapy for >/= to 2 weeks and off corticosteroids for >/= to 1 week.
Descripción

CNS metastases Systemic | Stable status Post Therapeutic radiology procedure | Adrenal Cortex Hormones Discontinued

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0205373
UMLS CUI [2,1]
C0205360
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C1522449
UMLS CUI [3,1]
C0001617
UMLS CUI [3,2]
C1444662
pregnant or nursing women.
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
patients who are primarily refactory to erlotinib.
Descripción

Erlotinib Refractory Primary

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1135135
UMLS CUI [1,2]
C0205269
UMLS CUI [1,3]
C0205225
Volver a la parte superior de la página

Similar models

Eligibility Non-small Cell Lung Cancer NCT00569114

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Non-small cell lung cancer recurrent TNM clinical staging | Pleural effusion
Item
histogically or pathologically determined relapsed/recurrent stage iiib (plueral effusion) or iv nsclc.
boolean
C0278517 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0032227 (UMLS CUI [2])
Measurable Disease | Evaluable Disease
Item
measurable or evaluable disease as defined by recist
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
Chemotherapy Regimen Quantity failed | Chemotherapy Refused
Item
must have failed at least one prior chemotherapy regimen or have refused chemotherapy.
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2,1])
C1705116 (UMLS CUI [2,2])
ECOG performance status
Item
ecog perfromance status of 0,1, or 2.
boolean
C1520224 (UMLS CUI [1])
Exclusion Criteria
Item
exclusion criteria (include but are not limited to):
boolean
C0680251 (UMLS CUI [1])
Therapeutic radiology procedure | Exception Therapeutic procedure Central Nervous System | Chemotherapy | Investigational New Drugs Non-Cytotoxic | Adrenal Cortex Hormones High dose | Adverse effects of medical drugs Recovery Lacking
Item
radiation therapy (excluding cns therapy) < 2 weeks, chemotherapy, non-cytotoxic investigational agents or high dose corticosteroids within 3 weeks of intitating therpy or patients who have not recovered from adverse effects due to agents administered more than 3 weeks earlier.
boolean
C1522449 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C3714787 (UMLS CUI [2,3])
C0392920 (UMLS CUI [3])
C0013230 (UMLS CUI [4,1])
C2827065 (UMLS CUI [4,2])
C0001617 (UMLS CUI [5,1])
C0444956 (UMLS CUI [5,2])
C0810090 (UMLS CUI [6,1])
C2004454 (UMLS CUI [6,2])
C0332268 (UMLS CUI [6,3])
Heart Disease New York Heart Association Classification
Item
evidence of new york heart associatation class iii or greater cardiac disease.
boolean
C0018799 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Myocardial Infarction | Cerebrovascular accident | Intervention Cardiovascular
Item
history of myocardial infarction, stroke, or cardiovascular intervention within the last 12 months.
boolean
C0027051 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
C0184661 (UMLS CUI [3,1])
C3887460 (UMLS CUI [3,2])
Antiplatelet Agents | Anticoagulants | Plavix | Coumadin
Item
patients on anti-platlet drugs or anticoagulants such as placix and coumadin.
boolean
C0085826 (UMLS CUI [1])
C0003280 (UMLS CUI [2])
C0633084 (UMLS CUI [3])
C0699129 (UMLS CUI [4])
CNS metastases Systemic | Stable status Post Therapeutic radiology procedure | Adrenal Cortex Hormones Discontinued
Item
systemic central nervous system metastases. the patient must be stable after radiotherapy for >/= to 2 weeks and off corticosteroids for >/= to 1 week.
boolean
C0686377 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205360 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
C0001617 (UMLS CUI [3,1])
C1444662 (UMLS CUI [3,2])
Pregnancy | Breast Feeding
Item
pregnant or nursing women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Erlotinib Refractory Primary
Item
patients who are primarily refactory to erlotinib.
boolean
C1135135 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0205225 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial